Search for a trial

Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study

This study has been transitioned to CTIS with ID 2023-509380-24-00 check the CTIS register for the current data. The purpose of this study is to investigate the effect of treatment with two courses of chemotherapy followed by immunotherapy. Immune…

LIVACOR Trial: Minimally invasive LIVer And simultaneous COlorectal Resection

The aim of the current study is to assess whether MI combined liver and colorectal resection for CRLMs and primary colorectal tumor can result in shorter time to functional recovery and hereby results indirectly in a lower postoperative complication…

Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study

This study has been transitioned to CTIS with ID 2024-513635-24-00 check the CTIS register for the current data. The aim of the study is to investigate the effectiveness and safety of the new drug nivolumab for the treatment of esophageal cancer. In…

Treatment of PERitoneal dissemination in Stomach Cancer patients with
cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the
PERISCOPE II study

This study has been transitioned to CTIS with ID 2023-510159-53-01 check the CTIS register for the current data. The primary aim of this study is to compare the overall survival between gastric cancer patients with limited peritoneal carcinomatosis…

Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer. The NICHE trial.

This study has been transitioned to CTIS with ID 2024-513314-35-00 check the CTIS register for the current data. Primary Objective: To determine the safety and feasibility of pre-operative immunotherapy in CRC. Additional Primary Objective for the…

Exercise during Neoadjuvant chemoradiation Treatment to improve rectal and esophageal cancer Outcome - pilot trial.

To 1) evaluate feasibility and fidelity of a three-arm RCT containing a twice-weekly exercise intervention supervised by a first-line (oncology) physiotherapist and a 5-day weekly in-hospital exercise intervention versus usual care in patients with…

INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL

To increase the major pathological response rate (< 10% vital tumor cells) to neoadjuvant treatment by integrating both trastuzumab and pertuzumab into perioperative chemotherapy for HER-2 positive, resectable gastric cancer.

A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

This study has been transitioned to CTIS with ID 2023-503248-15-00 check the CTIS register for the current data. • To assess which preoperative regimen provides superior event free survival 1 year after randomisation in patients with resectable…

Multicentre, randomised controlled trial comparing TRansanal minimal InvAsive Surgery (TAMIS) and endoscopic Submucosal dIsseCtion (ESD) for resection of non-pedunculated rectal lesions.

The aim of this study is to compare both procedures with regard to recurrence rates and complete (R0) resection rate, and to put this into perspective against the costs and complication rates of both strategies and the burden perceived by patients…

A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).

The primary objective is progression-free survival (PFS); defined as the time from randomization to the date of the first documented tumor progression; determined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or death due…

A first-in-human (FIH) study of IDRX-42 in participants with metastatic and/or unresectable
gastrointestinal stromal tumors (GIST)

This study has been transitioned to CTIS with ID 2024-514930-19-00 check the CTIS register for the current data. This study aims to evaluate IDRX-42 administered to participants with metastatic and/or surgically unresectable GIST.

Personalized prediction and regulation of 5-FU exposure

Primary objective:To determine the percentage of the patients that achieve optimal 5-FU exposure within two dose cycles of 5-FU, which is defined by an AUC target of 5-FU between 20 and 30 mg h/L or dose limiting toxicity.Secondary objectives:-To…

Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer - PelvEx II study

This study has been transitioned to CTIS with ID 2024-512526-28-00 check the CTIS register for the current data. The primary objective of this study is to determine whether the addition of induction chemotherapy to the neoadjuvant treatment of…

AN OPEN-LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7122290, A FIBROBLAST ACTIVATION PROTEIN-A (FAP) TARGETED 4-1BB LIGAND (CD137L), IN COMBINATION WITH CIBISATAMAB WITH OBINUTUZUMAB PRE-TREATMENT, IN
PARTICIPANTS WITH PREVIOUSLY TREATED, METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA

Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…

Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trial

The main objective is to determine the maximum tolerated dose (MTD) that will be the recommended radiation dose for the phase 2 study, in which we intend on using a MR-guided boost after SCRT in patients with intermediate risk rectal cancer to…

Endoscopic mucosal Resection versus Endoscopic subMucosal dissection fOr removal of Visible lesions in Barrett*s Esophagus with early neoplasia: a randomized controlled trial

We aim to compare EMR and ESD for removal of visible lesions in Barrett*s esophagus.

Early detection of cancer onset based on sensing field cancerization at the organ level in the alimentary tract using an integrated Raman/scattering modality for endoscopic real-time in vivo measurements

The primary objective involves the safety of in vivo Raman/scattering during endoscopy. Therefore, we will assess safety parameters (AEs, SAEs, SUSARs). Secondary objective involves the feasibility of the probe-based scattering/(stimulated) Raman…

A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecular signature

The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular…

External beam radiation therapy versus stent insertion for dysphagia relief in esophageal cancer: a multi-center randomized trial

Primary objectiveThe primary objective of this study is to compare the efficacy of EBRT versus SEMS insertion for palliation of malignant dysphagia in esophageal cancer patients at 4 weeks after start of treatment.Secondary objectivesSecondary…

A Phase III double-blind placebo-controlled Randomized Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

This study has been transitioned to CTIS with ID 2022-502324-48-00 check the CTIS register for the current data. To study the effect of 80mg aspirin (given orally once daily for five years) on fiveyear overall survival (OS) for stage II and III…